# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $10 to $2.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.
Wolfe Research analyst Andy Chen downgrades RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Peer Perform.
Barclays analyst Leon Wang downgrades RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Equal-Weight and lowers the price t...